Clinical trials: Glaucoma Patients
Open-Angle Glaucoma, Ocular Hypertension
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41
To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.
- Trial name
- NCT00047528
- Testing
- Alcon Investigational Agent
- Where
- United States
- Sponsor
- Alcon Research
Ocular Hypertension, Primary Open-Angle Glaucoma
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days.
- Trial name
- NCT01110499
- Testing
- AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Allergan
Ocular Hypertension, Glaucoma
A Study of Glaucoma or Ocular Hypertension in Patients Within the United States
Safety and efficacy study comparing between fixed combination latanoprost-timolol and its component parts.
- Trial name
- NCT00800267
- Testing
- latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%
- Where
- 53 sites in United States
- Volunteers
- 418 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Glaucoma Eye
MINIject in Patients With Open Angle Glaucoma Using Single Operator Delivery Tool
Study to assess safety and performance of MINIject SO627 in patients with open angle glaucoma.
- Trial name
- NCT03996200
- Testing
- MINIject CS627 implant
- Where
- 3 sites in Colombia, India and 1 more
- Volunteers
- 25 people
- Sponsor
- iSTAR Medical
Open-angle Glaucoma, Ocular Hypertension
Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)
This study was to compare the safety and efficacy of the preservative-free formulation of 0.0015% MK2452 (tafluprost) and preservative-free 0.5% timolol maleate in patients with open-angle glaucoma and ocular hypertension.
- Trial name
- NCT01026831
- Testing
- Preservative-Free Tafluprost, Comparator: timolol
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
Ocular Hypertension
IOP Patterns in Ocular Hypertensive Patients Newly Converted to Glaucoma vs Stable Ocular Hypertensive Patients
The purpose of the study is to assess the relationship between IOP pattern as recorded over 24 hours by using Triggerfish and quantified by acrophase scored dichotomously, and conversion to glaucoma in OHT patients (conversion…
- Trial name
- NCT02030886
- Testing
- Sensimed Triggersfish® (TF)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sensimed AG
Glaucoma, Ocular Hypertension
Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the safety and efficacy of both BETAXON and AZOPT in pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks.
- Trial name
- NCT00061516
- Testing
- BETAXON (levobetaxolol HCl), AZOPT (brinzolamide)
- Volunteers
- 78 people
- Sponsor
- Alcon Research
Glaucoma
Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma
The primary objective of the study is to assess the safety and tolerability of a 180μg/ml TID dose regimen of recombinant human nerve growth factor (rhNGF) eye drop solution administered over 8 weeks versus a vehicle control in…
- Trial name
- NGF-Glaucoma (NCT02855450)
- Testing
- rhNGF, Vehicle
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Dompé Farmaceutici S.p.A
Glaucoma, Ocular Hypertension
Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)
This study is comparing 2 medications for glaucoma and how effective they are at controlling glaucoma over the course of an entire day.
- Trial name
- NCT00108017
- Testing
- MK0507A, dorzolamide hydrochloride (+) timolol maleate, Comparator: timolol maleate, Duration of Treatment: Part 1) 6 wk timolol maleate run in
- Volunteers
- 330 people
- Sponsor
- Merck Sharp & Dohme LLC
Normal Tension Glaucoma
Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma
Evaluation of the optimal dose for the efficacy in reduction of intraocular pressure and safety of PHP-201 ophthalmic solution in patients with normal tension glaucoma
- Trial name
- NCT03106532
- Testing
- PHP-201 0.25% ophthalmic solution, PHP-201 0.5% ophthalmic solution
- Where
- South Korea
- Volunteers
- 119 people
- Sponsor
- pH Pharma
Primary Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
To evaluate the safety and efficacy of PF-04217329.
- Trial name
- NCT00572455
- Testing
- PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose
- Where
- 23 sites in United States
- Volunteers
- 318 people
- Sponsor
- Pfizer
Open Angle Glaucoma, Intraocular Pressure
An Extension Trial for Patients With Open-Angle Glaucoma Who Participated in the DF6-CL-20-01 Protocol.
The purpose of this study is to evaluate long term safety and effectiveness of the STREAMLINE® SURGICAL SYSTEM
- Trial name
- NCT06230393
- Testing
- STREAMLINE® SURGICAL SYSTEM
- Where
- Costa Rica
- Volunteers
- 17 people
- Sponsor
- New World Medical, Inc.
Hypertension, Glaucoma, Open-Angle
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma.
- Trial name
- NCT01493271
- Testing
- RO5093151
- Where
- 12 sites in United States, Bulgaria and 2 more
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination
The purpose of this study was to compare the safety and intraocular pressure (IOP)-lowering efficacy of a new fixed combination of brinzolamide/brimonidine (Brinz/Brim) to: its individual components (Brinz and Brim), and the…
- Trial name
- NCT00961649
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2%
- Volunteers
- 195 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28…
- Trial name
- SYLTAG (NCT02250612)
- Testing
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 184 people
- Sponsor
- Sylentis, S.A.
Primary Open-angle Glaucoma, Primary Angle-Closure Glaucoma
Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
This is a prospective, multi-centre, cross sectional observational study to determine the prevalence of ocular surface disease (OSD) in glaucoma patients, nationwide.
- Conditions
- Primary Open-angle Glaucoma, Primary Angle-Closure Glaucoma, Pseudoexfoliation Glaucoma, Pigment Dispersion Glaucoma
- Trial name
- NCT04609345
- Volunteers
- 400 people
- Sponsor
- Santen Pharma Malaysia Sdn Bhd
Glaucoma, Ocular Hypertension
Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.
- Trial name
- NCT01298700
- Testing
- bimatoprost 0.01% ophthalmic solution, bimatoprost 0.03% ophthalmic solution
- Where
- 50 sites in Belgium, Czechia and 8 more
- Volunteers
- 806 people
- Sponsor
- Allergan
Ocular Hypertension, Elevated IOP
Safety, Efficacy, and Pharmacokinetic Profile of DNB-001 in Subjects With Elevated Intraocular Pressure
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase 1I Study to Investigate the Safety, Efficacy, and Pharmacokinetic Profile of Twice-Daily DNB-001 in Previously Untreated Patients with intraocular…
- Conditions
- Ocular Hypertension, Elevated IOP, Glaucoma
- Trial name
- DNB-001 (NCT00683501)
- Testing
- DNB-001
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Danube Pharmaceuticals, Inc.
Open Angle Glaucoma, Ocular Hypertension
Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH
This study is a double-masked, randomized, parallel group study in patients with open angle glaucoma or ocular hypertension. The aim of this study is to verify the efficacy of the fixed combination of Latanoprost 50 mcg / mL /…
- Trial name
- NCT01721707
- Testing
- Latanoprost+Brinzolamide combination, Latanoprost
- Where
- Brazil
- Sponsor
- Adapt Produtos Oftalmológicos Ltda.
Glaucoma, Ocular Hypertension
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
The objective of this dose-escalation study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension or primary open-angle glaucoma.
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Trial name
- NCT01693315
- Testing
- AMA0076
- Where
- 6 sites in United States
- Volunteers
- 82 people
- Sponsor
- Amakem, NV